Eisai Announces China Approval for Liver Cancer Treatment

Eisai and Merck/MSD  announced the China National Medical Products Administration (NMPA) approved Lenvima^® (lenvatinib) as a first-line treatment for unresectable hepatocellular carcinoma. It is the first China approval for Lenvima, where the incidence of HCC is high, and the first new systemic therapy approved in China for first-line treatment of unresectable HCC in ten years. The NMPA completed its review in 10 months under Priority Review procedures. More details....

Stock Symbols: (TYO: 4523) (NYSE: MRK)

Share this with colleagues:

Original Article: Eisai Announces China Approval for Liver Cancer Treatment

More From BioPortfolio on "Eisai Announces China Approval for Liver Cancer Treatment"